BioMed Research International / 2010 / Article / Fig 2

Research Article

L6E9 Myoblasts Are Deficient of Myostatin and Additional TGF- Members Are Candidates to Developmentally Control Their Fiber Formation

Figure 2

(a) Morphological visualization of L6E9 myotubes, untreated (control, day 5) or treated at day 3 with 100 or 500 ng/mL recombinant myostatin (r-mstn) up to 48 hours, as depicted by phase contrast pictures after Giemsa staining. Bar = 1 0 0 𝜇 m . (b) The graph represents the quantification of average size in L6E9 myotubes, treated with 100 or 500 ng/mL r-mstn up to 48 hours as compared to control. 𝑃 < . 0 5 versus control. (c) Immunoblotting shows that MyHC levels are downregulated in L6E9 myotubes exposed to r-mstn (100 or 500 ng/mL) up to 48 hours as compared to untreated cells. Tubulin was used as loading control. (d) Semiquantitative RT-PCR analysis was performed to detect the expression levels of myostatin, p21, follistatin, ActRIIa, and ActRIIb in L6E9 myotubes (day 3) treated with r-mstn (500 ng/mL) up to 48 hours compared to untreated. Gapdh amplification was performed as loading control.
326909.fig.002a
(a)
326909.fig.002b
(b)
326909.fig.002c
(c)
326909.fig.002d
(d)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.